Tomorrow is the KU Cancer Center Post San Antonio Review! Our expert speakers have lots of innovation and highlights from #SABCS to share with you. Register free: sanantonioupdate.com #BCSM

With great sadness we join the oncology community in mourning the passing of Angelo Di Leo, a giant in the #breastcancer field and recipient of the ESMO Lifetime Achievement Award in 2019 and member of the Annals of Oncology Editorial Board. Our thoughts are with his loved ones.

Dr. Rinath Jeselsohn (Rinath Jeselsohn) and colleagues published a new study examining how a "A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular #BreastCancer." #bcsm pubmed.ncbi.nlm.nih.gov/35950920/

Biomarkers of response and resistance - Luca Malorni Oncologia Prato #SABCS22

The @SABCS22 Meeting News write-up, "Osborne Symposium highlights growing understanding of HER2, ER crosstalk" featured comments from Dr. Rinath Jeselsohn's Rinath Jeselsohn talk. Read the full article here: sabcsmeetingnews.org/osborne-sympos…

Great job!👏👏👏

Susan G. Komen is excited to announce that nine world-renowned breast cancer researchers will join the organization as Komen Scholars to help guide Komen’s work so that people who have been diagnosed with breast cancer can live longer, better lives. bit.ly/3Vh4NOS

Please join Agostina Nardone at the poster session presenting “AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance” #ESMOBreast23

New📰Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive #breastcancer published in Cancer Research. Rinath Jeselsohn Otto Metzger Sara Tolaney Dr. E Mittendorf Nabihah Tayob Fulltext here: pubmed.ncbi.nlm.nih.gov/37450351/

Beautiful discussion by Shom Goel NF1 loss assoc 2/endocrine resistance NF1 low/mutant tumors more sensitive to cdk 4/6i NF1 loss leads to ⬆️phosphorylation of cdk4 + Rb Functional loss of NF1 may be more common in ER+ BC than previously thought. OncoAlert #SABCS23

Rinath Jeselsohn from Dana-Farber’s Breast Oncology Center presenting sophisticated analysis of BL and serial ctDNA from PACE trial, elucidating mechanisms of resistance to ET and CDK4/6i. And moderated by Ada Waks! #SABCS23 Dana-Farber

.Charles Swanton discussed "Breast cancer evolution, immune evasion, and metastasis driven by chromosomal instability" during his plenary lecture this afternoon at #SABCS23. @UTHealthSAMDA AACR

Svitlana Tyekucheva, PhD leads statistical collaboration for PYTHIA, a phase II global trial evaluating #genomics & progression free survival for post-menopausal women with advanced #breastcancer whose disease progressed after hormone therapy: bit.ly/3S8E5Iq ETOP IBCSG Partners Foundation

Just published ‼️our latest report on the ctDNA mutational analysis within the TREnd trial exploring palbociclib alone or in combo with ET in metatstatic breast cancer ascopubs.org/doi/full/10.12… Fondazione AIRC per la ricerca sul cancro G Curigliano MD PhD Carmen Criscitiello Cristina Guarducci LauraBiga @benelli_matteo

New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in Clinical Cancer Research. Cristina Guarducci Rinath Jeselsohn Geoffrey Shapiro MD PhD Albert Grinshpun ➡️pubmed.ncbi.nlm.nih.gov/38381406/

New study examining pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer now published in npj Journals #BreastCancer. 👉pubmed.ncbi.nlm.nih.gov/38851818/ Albert Grinshpun Rinath Jeselsohn Nancy Lin, MD Sheheryar Kabraji @gkirkner Cristina Guarducci @SantagataLab